ELUSYS & BIODEFENSE
US GOVERNMENT CONTRACT EXPERIENCE
Elusys has been working in partnership with the US Government on development of biowarfare countermeasures since 1999. The Company has received over $51 Million in government funding from the Department of Defense (DoD), the National Institutes of Health (NIH) and the Biomedical Advanced Research and Development Authority (BARDA) of Health and Human Services to advance Anthim®, an anti-toxin for the prophylaxis and treatment of anthrax infection, towards procurement into the Strategic National Stockpile and Food and Drug Administration (FDA) licensure.
Most recently, Elusys has been awarded a contract totally up to $143 Million to support final non-clinical and clinical development and commercial-scale manufacturing for Anthim. We have built a strong management and development team with experience in all facets of drug development. We are proud that we have met all our contract goals and milestones and have received outstanding ratings from the government as a subcontractor.
Over the past 10 years, Elusys has continued to play a key role in working with the government to further improve our nation’s ability to develop and stockpile effective countermeasures.
- Elusys participated early on to help establish the “Animal Rule” – a mechanism that provides the FDA a path for licensing drugs where efficacy cannot be established by typical clinical efficacy trials.
- Elusys has testified on Capital Hill to brief members of Congress on issues related to countermeasure development. Our efforts along with many others helped advance the establishment of “BioShield” in 2004 - a $5.6 Billion Dollar Special Reserve Fund for the stockpiling of countermeasures against anthrax and other bioterrorism agents.
- Elusys met numerous times with members of Congress, particularly the HELP committee, to support establishment of the BARDA – a group within HHS dedicated to funding late stage countermeasure development.